Trial Profile
A phase I/II study of Erlotinib plus WT1-W10 peptide vaccine for previously treated Non Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; WT1-W10 peptide vaccine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Dec 2012 New trial record